Development of a BoHV-4 viral vector expressing tgD of BoHV-1 and evaluation of its immunogenicity in mouse model


Creative Commons License

BİLGE DAĞALP S., Farzani T. A., Dogan F., Yoldar Z. A., ÖZKUL A., ALKAN F., ...Daha Fazla

Brazilian Journal of Microbiology, cilt.52, sa.3, ss.1119-1133, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 52 Sayı: 3
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1007/s42770-021-00525-z
  • Dergi Adı: Brazilian Journal of Microbiology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Aquatic Science & Fisheries Abstracts (ASFA), BIOSIS, CAB Abstracts, EMBASE, Food Science & Technology Abstracts, MEDLINE, Veterinary Science Database, Directory of Open Access Journals
  • Sayfa Sayıları: ss.1119-1133
  • Anahtar Kelimeler: Bovine herpesvirus 4, Viral vector, Bovine herpesvirus 1, TgD, Immune response, BOVINE HERPESVIRUS-4, REPLICATION-COMPETENT, PROTECTIVE IMMUNITY, GLYCOPROTEIN GD, IN-VITRO, DNA, GENOME, IMMUNIZATION, ANTIBODIES, EFFICACY
  • Ankara Üniversitesi Adresli: Evet

Özet

© 2021, Sociedade Brasileira de Microbiologia.In recent years, Bovine herpesvirus 4 (BoHV-4) has emerged as an attractive gene delivery viral vector, mainly for vaccination purposes in the veterinary field. In the present study, a new infectious clone of the BoHV-4 genome carrying a bacterial artificial chromosome vector (BoHV-4-BAC) was developed by homologous recombination in mammalian cell culture and bacterial systems, and exploited to express a truncated form of glycoprotein D (tgD) of Bovine herpesvirus 1 (BoHV-1) (BoHV-4-tgD∆TK) as a vaccine candidate. This construct’s immunogenicity was compared to a DNA vector expressing the same antigen (pC-tgD) in a BALB/c mouse model. After the mice were immunized, total and specific antibody responses, cytokine responses, total splenocyte cells proliferation/cytotoxicity, and virus neutralization assays were conducted to analyze the immune response elicited by both constructs. Mice from both vaccine groups developed significant humoral and cellular immune responses after a booster dose regime was conducted on day 28 post-injection. In almost all immunological assays, BoHV-4-tgDΔTK induced as high an immune response as pC-tgD. In both vaccine constructs, neutralizing antibodies were a significant determining factor in protection against BoHV-1, even after the first injection. We conclude that a BoHV-4-based viral vector offers an effective immunization strategy as an alternative to DNA-based immunization platforms, at least to combat BoHV-1.